Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3082% above fair value
$1.72−0.06 (-3.37%)
Close on Nov 18, 2026Market cap $765.32MP/E –Yield –
Lexicon Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Lexicon Pharmaceuticals's total assets was $250.06M at Jun 30, 2026. For fiscal 2025 it was $184.99M, down 38.0% from the year before. Over ten years it grew -11.8% a year on average. The highest annual figure on record is $651.96M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.99M | -38.0% |
| FY2024 | Dec 31, 2024 | $298.42M | +30.1% |
| FY2023 | Dec 31, 2023 | $229.43M | +18.1% |
| FY2022 | Dec 31, 2022 | $194.30M | +41.9% |
| FY2021 | Dec 31, 2021 | $136.91M | -32.8% |
| FY2020 | Dec 31, 2020 | $203.79M | -51.2% |
| FY2019 | Dec 31, 2019 | $417.72M | +47.0% |
| FY2018 | Dec 31, 2018 | $284.14M | -34.9% |
| FY2017 | Dec 31, 2017 | $436.54M | -8.2% |
| FY2016 | Dec 31, 2016 | $475.63M | -27.0% |
| FY2015 | Dec 31, 2015 | $651.96M | +38.3% |
| FY2014 | Dec 31, 2014 | $471.38M | +71.9% |
| FY2013 | Dec 31, 2013 | $274.16M | -26.3% |
| FY2012 | Dec 31, 2012 | $371.78M | -13.6% |
| FY2011 | Dec 31, 2011 | $430.51M | +17.3% |
| FY2010 | Dec 31, 2010 | $366.88M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $250.06M | +10.9% |
| Q1 FY2026 | Mar 31, 2026 | $268.82M | -9.7% |
| Q4 FY2025 | Dec 31, 2025 | $184.99M | -38.0% |
| Q3 FY2025 | Sep 30, 2025 | $205.93M | -35.9% |
| Q2 FY2025 | Jun 30, 2025 | $225.58M | -39.6% |
| Q1 FY2025 | Mar 31, 2025 | $297.67M | -28.7% |
| Q4 FY2024 | Dec 31, 2024 | $298.42M | +30.1% |
| Q3 FY2024 | Sep 30, 2024 | $321.12M | +16.1% |
| Q2 FY2024 | Jun 30, 2024 | $373.36M | +17.9% |
| Q1 FY2024 | Mar 31, 2024 | $417.22M | +156.4% |
| Q4 FY2023 | Dec 31, 2023 | $229.43M | +18.1% |
| Q3 FY2023 | Sep 30, 2023 | $276.48M | +44.2% |
| Q2 FY2023 | Jun 30, 2023 | $316.72M | +182.0% |
| Q1 FY2023 | Mar 31, 2023 | $162.72M | +19.5% |
| Q4 FY2022 | Dec 31, 2022 | $194.30M | +41.9% |
| Q3 FY2022 | Sep 30, 2022 | $191.69M | +11.2% |
| Q2 FY2022 | Jun 30, 2022 | $112.33M | -34.6% |
| Q1 FY2022 | Mar 31, 2022 | $136.18M | -29.5% |
| Q4 FY2021 | Dec 31, 2021 | $136.91M | -32.8% |
| Q3 FY2021 | Sep 30, 2021 | $172.33M | -3.7% |
| Q2 FY2021 | Jun 30, 2021 | $171.67M | -46.8% |
| Q1 FY2021 | Mar 31, 2021 | $193.26M | -47.8% |
| Q4 FY2020 | Dec 31, 2020 | $203.79M | -51.2% |
| Q3 FY2020 | Sep 30, 2020 | $178.93M | -59.8% |
| Q2 FY2020 | Jun 30, 2020 | $322.54M | +38.3% |
| Q1 FY2020 | Mar 31, 2020 | $370.57M | +43.3% |
| Q4 FY2019 | Dec 31, 2019 | $417.72M | +47.0% |
| Q3 FY2019 | Sep 30, 2019 | $444.59M | +43.3% |
| Q2 FY2019 | Jun 30, 2019 | $233.14M | -30.0% |
| Q1 FY2019 | Mar 31, 2019 | $258.52M | -33.2% |
| Q4 FY2018 | Dec 31, 2018 | $284.14M | -34.9% |
| Q3 FY2018 | Sep 30, 2018 | $310.19M | -5.9% |
| Q2 FY2018 | Jun 30, 2018 | $332.94M | -8.4% |
| Q1 FY2018 | Mar 31, 2018 | $386.81M | -2.4% |
| Q4 FY2017 | Dec 31, 2017 | $436.54M | -8.2% |
| Q3 FY2017 | Sep 30, 2017 | $329.49M | -36.3% |
| Q2 FY2017 | Jun 30, 2017 | $363.51M | – |
| Q1 FY2017 | Mar 31, 2017 | $396.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $475.63M | – |
| Q3 FY2016 | Sep 30, 2016 | $516.95M | – |
See a number that looks wrong?